Sanara MedTechSMTI -2.50%72 PS Ratio is 1.98 as of Jul. 08, 2026, which is 33% below its 10-year median of 2.95. GuruFocus rates SMTI with a GF Score™ of 72/100 and a GF Value™ of $45.67 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 804 Medical Devices & Instruments companies, Sanara MedTech ranks better than 61.82% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Sanara MedTech's share price is $24.17.
Sanara MedTech's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $12.22. Hence, Sanara MedTech's PS Ratio for today is 1.98.
The historical rank and industry rank for Sanara MedTech's PS Ratio or its related term are showing as below:
SMTI'
s PS Ratio Range Over the Past 10 Years
Min: 0.36 Med: 2.95 Max: 20.02
Current: 2
During the past 13 years, Sanara MedTech's highest PS Ratio was 20.02. The lowest was 0.36. And the median was 2.95.
SMTI's PS Ratio is ranked better than 61.82% of 804
companies
in the Medical Devices & Instruments industry
Industry Median: 2.935
vs SMTI: 2.00
Sanara MedTech Inc revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Sanara MedTech was 13.70% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 27.30% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 37.40% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 13.50% per year.
During the past 13 years, Sanara MedTech's highest 3-Year average Revenue per Share Growth Rate was 476.90% per year. The lowest was -16.30% per year. And the median was 13.40% per year.
Back to Basics: PS Ratio
Sanara MedTech (NAS:SMTI) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Sanara MedTech PS Ratio Related Terms
Sanara MedTech PS Ratio Historical Data
* Premium members only.
The historical data trend for Sanara MedTech's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Sanara MedTech's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sanara MedTech PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sanara MedTech's PS Ratio distribution charts can be found below:
* The bar in red indicates where Sanara MedTech's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Sanara MedTech's Share Price of today is $24.17. Sanara MedTech's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $12.22.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Sanara MedTech (SMTI) has a PS Ratio of 1.98 as of Jul. 08, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Sanara MedTech and its competitors. This is 33% below median its historical median of 2.95. Over the past decade, Sanara MedTech's PS Ratio has ranged from 0.36 to 20.02. According to the industry distribution chart, Sanara MedTech ranks #307 out of 804 companies in the Medical Devices & Instruments industry, placing it in the top 38.2%.
Is Sanara MedTech's PS Ratio too high?
Sanara MedTech's current PS Ratio of 1.98 is 33% below median its 10-year median of 2.95. Over the past 10 years, this metric has ranged from a low of 0.36 to a high of 20.02. The Medical Devices & Instruments industry median PS Ratio is 2.94. Sanara MedTech's value of 1.98 is 32.5% below this industry median. Based on the distribution chart, Sanara MedTech ranks #307 out of 804 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Sanara MedTech has a GF Score™ of 72/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sanara MedTech's PS Ratio compare to EMBC and KRMD?
According to the Medical Devices & Instruments industry distribution chart, Sanara MedTech ranks #307 out of 804 companies for PS Ratio. This puts Sanara MedTech in the upper half of its industry. The industry median PS Ratio is 2.94. Sanara MedTech's value of 1.98 is 32.5% below this benchmark. Historically, Sanara MedTech's own PS Ratio has ranged from 0.36 to 20.02 over the past decade. While the company's 10-year median is 2.95 vs. the industry median of 2.94, Sanara MedTech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.94, based on 804 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sanara MedTech's current PS Ratio of 1.98 is 32.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Sanara MedTech and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sanara MedTech's current PS Ratio is 1.98, which is 33% below median its own 10-year median of 2.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanara MedTech stock overvalued right now?
Based on GuruFocus' analysis, Sanara MedTech (SMTI) is currently considered Possible Value Trap. The stock's GF Value™ is $45.67, compared to a current price of $24.17 — trading 47.1% below its estimated fair value. The current PS Ratio is 1.98, which is 33% below median its 10-year median of 2.95 and 32.5% below the Medical Devices & Instruments industry median of 2.94. Sanara MedTech's overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Sanara MedTech (SMTI), the current PS Ratio is 1.98 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sanara MedTech (SMTI) Overvalued in 2026?
Based on GuruFocus' analysis, Sanara MedTech stock appears to be undervalued.
The current stock price of $24.17 is trading 47.1% below its estimated GF Value™ of $45.67.
GuruFocus considers Sanara MedTech to be Possible Value Trap.
Key valuation signals for SMTI:
PS Ratio: 1.98 (33% below median its 10-year median of 2.95)
GF Value™: $45.67 vs. price of $24.17 (47.1% below fair value)
Industry Position: 32.5% below the Medical Devices & Instruments median (#307 of 804)
No single metric tells the full story. See the SMTI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sanara MedTech Inc is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. It markets and sells soft tissue repair and bone fusion products for use in operating rooms and sterile environments. Its soft tissue repair products include CellerateRX Surgical Powder, a hydrolyzed collagen used in management of surgical wounds, and BIASURGE Surgical Solution, a sterile no-rinse solution for wound irrigation, while its bone fusion products include BiFORM Bioactive Moldable Matrix, an osteoconductive implant that supports bone growth, and ALLOCYTE Plus Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers.
72GF Score
Get the complete analysis for SMTI
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SMTI has been successfully added to your 
